Company intelligence / Profile preview
CoImmune, Inc.
Durham, North Carolina, United Statesprnewswire.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Running a Phase 2b trial for lead asset CMN-001 in advanced renal cell carcinoma. Developing CAR-CIK technology for clinical development in acute lymphoblastic leukemia.
- Therapeutic areas
- Oncology
- Modalities
- Cell-based therapeuticsCAR-CIK (cytokine-induced killer cells)Dendritic cell-based immunotherapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Formula Pharmaceuticals (merged)Tettamanti Foundation of MonzaSan Gerardo Hospital in Monza
Beyond the preview
Go deeper on CoImmune, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoImmune, Inc..